← Back to Search

Other

VLX-1005 for Heparin Induced Thrombocytopenia

Phase 1
Waitlist Available
Led By Allen Hunt, MBA
Research Sponsored by Veralox Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 - 30 days
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group

Summary

This trial tests a new drug, VLX-1005, alone and with another drug, in healthy individuals. It aims to ensure safety and understand how these drugs interact. The goal is to see how they work in the body and their effects, focusing on safety and bleeding risks.

Eligible Conditions
  • Heparin Induced Thrombocytopenia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 - 30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 - 30 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Effects of VLX-1005 on AUC(inf) of argatroban
Effects of VLX-1005 on Cmax of argatroban
Effects of VLX-1005 on PFA-100
+7 more
Secondary study objectives
Effects of VLX-1005 on 12-HETE
Effects of argatroban on 12-HETE
Safety as measured by incidence of Treatment Emergent Adverse Events

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: VLX-1005 and ArgatrobanExperimental Treatment2 Interventions
Intravenous co-administration of VLX-1005 and argatroban with measurements of PK and PD
Group II: VLX-1005Experimental Treatment1 Intervention
Intravenous administration of VLX-1005 with measurements of PK and PD
Group III: ArgatrobanActive Control1 Intervention
Intravenous administration of argatroban with measurements of PK and PD
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
VLX-1005
2022
Completed Phase 1
~110
Argatroban
FDA approved

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Veralox TherapeuticsLead Sponsor
2 Previous Clinical Trials
156 Total Patients Enrolled
CelerionIndustry Sponsor
83 Previous Clinical Trials
7,854 Total Patients Enrolled
Allen Hunt, MBAPrincipal InvestigatorCelerion
~3 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top